Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
881-900 of 2,120 trials

X-linked Hypophosphatemia: KK8123 Treatment Study

We are testing a new treatment called KK8123 in adults with X-linked hypophosphatemia to see if it is safe and how it affects phosphorus levels in the body.

X-linked HypophosphatemiaSafety phase (I)No PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyInternal Medicine

Crohn's Disease: Vedolizumab with Upadacitinib

We are studying whether a combination of vedolizumab and upadacitinib helps improve symptoms in adults with moderately to severely active Crohn's disease compared to vedolizumab alone.

Crohn's Disease>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Raynaud’s Phenomenon: Sodium Thiosulfate Study

We are exploring how different doses of an intravenous medication, sodium thiosulfate, may help improve blood flow in people with Raynaud’s phenomenon. The study will also look at the safety and how the body reacts to the treatment.

Raynaud's PhenomenonEfficacy phase (II)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Advanced Solid Tumors: Datopotamab Deruxtecan Study

We are studying a new treatment for patients with advanced or metastatic solid tumors to see how well it works and its safety when used alone or with other cancer drugs.

Various Types of CancerEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Frontotemporal Dementia: AVB-101 Treatment Study

We are testing a new treatment called AVB-101 for individuals with frontotemporal dementia due to specific genetic mutations. The study aims to assess its safety and early effects on symptoms.

Frontotemporal Dementia>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementNeurology

Volrustomig for Advanced Non-Small Cell Lung Cancer

We are studying the safety and effectiveness of volrustomig combined with chemotherapy and other drugs for patients with advanced or metastatic non-small cell lung cancer. This research aims to find better treatment options for this condition.

Non-small Cell Lung CancerSolid TumorsSQ, NSQ NSCLCEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Cancer Treatment: PET Tracers and T Cell Activity

We are studying how two PET tracers relate to T cell changes in cancer patients before surgery. This research may help us understand T cell activation and its impact on tumor response.

Breast CancerEsophageal CancerMelanoma3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Soft-Tissue Sarcoma: Intensified Chemotherapy Study

We are investigating whether adding extra chemotherapy cycles helps high-risk patients with resectable soft-tissue sarcomas have better outcomes after surgery. This study compares the effects of different chemotherapy regimens on survival rates.

Resectable Non-Metastatic Soft-Tissue Sarcoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementOncology

Advanced Solid Tumors: Atezolizumab with EIK10001 and Radiation

We are studying a new treatment combining atezolizumab, EIK10001, and radiation for patients with advanced solid tumors like pancreatic cancer and triple-negative breast cancer. This trial aims to evaluate how well this combination works in controlling cancer.

Metastatic Solid Tumors>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineOncology

Advanced Sarcomas: Pembrolizumab and Cabozantinib Study

We are investigating the effects of a combination of pembrolizumab and cabozantinib in patients with advanced sarcomas. The goal is to see if this treatment can help prevent disease progression and improve overall outcomes.

Advanced Metastatic Sarcomas>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Advanced Sarcoma: Bintrafusp Alfa and Doxorubicin

We are studying a new treatment combining Bintrafusp alfa with doxorubicin for patients with advanced sarcoma. The goal is to see if this combination improves tumor response and safety compared to standard treatments.

Soft-Tissue Sarcomas>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Colorectal Cancer: RO7198457 Treatment Study

We are comparing a new treatment called RO7198457 to watchful waiting in patients with high-risk, resected Stage II and Stage III colorectal cancer. The goal is to see if the new treatment can help prevent cancer recurrence better than simply monitoring.

Stage II/Stage III Rectal Cancer or Stage II (High Risk)/Stage III Colon Cancer>2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Geographic Atrophy: Pozelimab and Cemdisiran Study

We are investigating whether a new treatment combining pozelimab with cemdisiran helps slow the progression of geographic atrophy in adults. This study aims to understand its effects on vision and safety compared to cemdisiran alone.

Geographic Atrophy from Age-Related Macular Degeneration>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicineOphthalmology

Melanoma: [68Ga]Ga-FAPI PET/CT Imaging Study

We are testing a new imaging method to see how well immune checkpoint inhibitor therapy works in patients with advanced melanoma. This study aims to improve response evaluation during treatment.

Malignant Melanoma6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesDermatologyOncology

Colorectal Cancer: Intermittent vs. Continuous Treatment with Panitumumab

We are studying whether an intermittent treatment of Panitumumab with FOLFIRI is as effective as continuous treatment for patients with metastatic left-sided colorectal cancer. The trial also aims to assess safety and quality of life for participants.

Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Autoimmune Diseases: Ublituximab Administration Study

We are evaluating how well ublituximab works when given through an IV or as a subcutaneous injection in patients with autoimmune diseases. This study aims to understand the drug's effects and how it moves through the body.

Relapsing Multiple SclerosisMyasthenia Gravis1-2 yearsSafety phase (I)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineNeurology

Guselkumab for Kids with Inflammatory Conditions

We are studying the long-term safety of guselkumab in children with ulcerative colitis, Crohn’s disease, or juvenile psoriatic arthritis. This research aims to ensure the medication is safe for young patients.

Crohn's DiseaseJuvenile Psoriatic ArthritisUlcerative Colitis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementDermatologyGastroenterologyRheumatology

HER2+ Cancer Treatment: Zongertinib Study

We are exploring the safety and effectiveness of zongertinib, alone and with other treatments, for patients with advanced HER2+ metastatic breast and gastric cancers. This study aims to find the best dose and understand how it may help manage these cancers.

Gastroesophageal Junction AdenocarcinomaEsophageal AdenocarcinomaMetastatic Breast CancerSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyOncology

RAS G12C-Mutated Non-Small Cell Lung Cancer: RMC-6291 Study

We are studying a new treatment combining RMC-6291 with pembrolizumab and other therapies for patients with RAS G12C-mutated lung cancer. The goal is to evaluate safety and early signs of effectiveness.

Non-small Cell Lung CancerSafety phase (I)No PlaceboInvestigational MedicinesOncologyPulmonology

Non-Small Cell Lung Cancer: RMC-6236 with Pembrolizumab

We are studying a new treatment combining RMC-6236 and pembrolizumab for patients with advanced RAS-mutated non-small cell lung cancer. The goal is to evaluate its safety and potential effectiveness, with or without chemotherapy.

Non-small Cell Lung CancerSafety phase (I)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology